BRPI0917148A2 - anticorpos anti-cd5 - Google Patents

anticorpos anti-cd5

Info

Publication number: BRPI0917148A2
Authority: BR; Brazil
Prior art keywords: antibodies
Prior art date: 2008-08-29

Application number

BRPI0917148A

Other languages

English (en)

Inventor

Charles Pyke

Josephine L K Klitgaard

Klaus Koefoed

Mikkel Wandhal Pedersen

Original Assignee

Symphogen As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-08-29

Filing date

2009-08-28

Publication date

2015-12-01

2009-08-28 Application filed by Symphogen As filed Critical Symphogen As

2015-12-01 Publication of BRPI0917148A2 publication Critical patent/BRPI0917148A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Biophysics (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Public Health (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Oncology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BRPI0917148A 2008-08-29 2009-08-28 anticorpos anti-cd5 BRPI0917148A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA200801191		2008-08-29
US9370008P	2008-09-02	2008-09-02
PCT/DK2009/050218 WO2010022737A1 (en)	2008-08-29	2009-08-28	Anti-cd5 antibodies

Publications (1)

Publication Number	Publication Date
BRPI0917148A2 true BRPI0917148A2 (pt)	2015-12-01

Family

ID=40677719

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0917148A BRPI0917148A2 (pt)	2008-08-29	2009-08-28	anticorpos anti-cd5

Country Status (15)

Country	Link
US (1)	US20110250203A1 (pt)
EP (1)	EP2328932A1 (pt)
JP (1)	JP2012500815A (pt)
KR (1)	KR20110050541A (pt)
CN (1)	CN102137873A (pt)
AU (1)	AU2009287164A1 (pt)
BR (1)	BRPI0917148A2 (pt)
CA (1)	CA2735279A1 (pt)
IL (1)	IL209975A0 (pt)
MX (1)	MX2011000970A (pt)
NZ (1)	NZ591153A (pt)
RU (1)	RU2011111640A (pt)
TW (1)	TW201011045A (pt)
WO (1)	WO2010022737A1 (pt)
ZA (1)	ZA201100300B (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011103490A2 (en)	2010-02-18	2011-08-25	The Regents Of The University Of California	INTEGRIN αVβ8 NEUTRALIZING ANTIBODY
JP2014510080A (ja) *	2011-03-09	2014-04-24	セントローズ，エルエルシー	細胞外標的化薬物複合体
WO2013023162A2 (en) *	2011-08-10	2013-02-14	Genus Oncology, Llc	Anti-muc1 antibodies for cancer diagnostics
SG2014014237A (en) *	2011-08-17	2014-07-30	Univ California	Antibodies that bind integrin alpha-v beta-8
CN102786595B (zh) *	2012-08-03	2014-04-23	无锡傲锐东源生物科技有限公司	抗cd5蛋白单克隆抗体及其用途
AU2013364043B2 (en)	2012-12-21	2018-01-04	Seagen Inc.	Anti-NTB-A antibodies and related compositions and methods
WO2014102299A2 (en) *	2012-12-27	2014-07-03	Sanofi	Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
CA3211863A1 (en)	2013-01-14	2014-07-17	Xencor, Inc.	Novel heterodimeric proteins
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
CA2939034A1 (en) *	2014-02-19	2015-08-27	Cangene Corporation	Methods of modulating an immune response
DK3223845T3 (da)	2014-11-26	2021-08-16	Xencor Inc	Heterodimere antistoffer, der binder cd3 og cd20
PE20171103A1 (es)	2014-11-26	2017-08-07	Xencor Inc	Anticuerpos heterodimericos que se unen a cd3 y cd38
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
US20170151281A1 (en)	2015-02-19	2017-06-01	Batu Biologics, Inc.	Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
MA41962A (fr)	2015-04-23	2018-02-28	Baylor College Medicine	Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t
US11369663B2 (en) *	2016-06-07	2022-06-28	Washington University	Detection of CD5 and methods and compositions for modulating CD5
EP3475304B1 (en)	2016-06-28	2022-03-23	Xencor, Inc.	Heterodimeric antibodies that bind somatostatin receptor 2
WO2018017864A2 (en) *	2016-07-20	2018-01-25	Oncomed Pharmaceuticals, Inc.	Pvrig-binding agents and uses thereof
JP7072576B2 (ja) *	2016-09-16	2022-05-20	シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド	抗ｐｄ－１抗体
US20180128545A1 (en)	2016-11-08	2018-05-10	Berry Metal Company	Modular furnace cooling wall
CN112272563A (zh)	2017-11-08	2021-01-26	Xencor股份有限公司	使用新颖抗pd-1序列的双特异性和单特异性抗体
AU2018374283A1 (en)	2017-11-29	2020-06-04	Magenta Therapeutics, Inc.	Compositions and methods for the depletion of CD5+ cells
US10982006B2 (en)	2018-04-04	2021-04-20	Xencor, Inc.	Heterodimeric antibodies that bind fibroblast activation protein
WO2020097193A1 (en)	2018-11-06	2020-05-14	The Regents Of The University Of California	Chimeric antigen receptors for phagocytosis
US11673964B2 (en)	2018-12-19	2023-06-13	The Trustees Of The University Of Pennsylvania	Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias
JP2022530026A (ja)	2019-04-24	2022-06-27	ハイデルベルクファルマリサーチゲゼルシャフトミットベシュレンクテルハフツング	アマトキシン抗体薬物複合体及びその使用
US11026973B2 (en)	2019-04-30	2021-06-08	Myeloid Therapeutics, Inc.	Engineered phagocytic receptor compositions and methods of use thereof
WO2021046243A2 (en)	2019-09-03	2021-03-11	Myeloid Therapeutics, Inc.	Methods and compositions for genomic integration
US10980836B1 (en)	2019-12-11	2021-04-20	Myeloid Therapeutics, Inc.	Therapeutic cell compositions and methods of manufacturing and use thereof
BR112022022558A2 (pt)	2020-05-08	2022-12-13	Academia Sinica	Polipeptídeo de hemaglutinina (ha) do vírus influenza quimérico, composição imunogênica, método de imunização de um indivíduo contra o vírus influenza ou prevenção de uma doença do vírus influenza, polinucleotídeo recombinante, vetor e célula hospedeira
WO2021231982A1 (en) *	2020-05-14	2021-11-18	City Of Hope	Smc1a antibodies and uses thereof
US11919956B2 (en)	2020-05-14	2024-03-05	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
EP3915641A1 (en) *	2020-05-27	2021-12-01	International-Drug-Development-Biotech	Anti-cd5 antibodies and methods of use thereof
US20230340141A1 (en) *	2020-08-21	2023-10-26	City Of Hope	Anti-cd5 antibody compositions and uses thereof
WO2022056459A1 (en)	2020-09-14	2022-03-17	Vor Biopharma, Inc.	Compositions and methods for cd5 modification
EP4240367A4 (en)	2020-11-04	2024-10-16	Myeloid Therapeutics, Inc.	MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
US20220144956A1 (en) *	2020-11-06	2022-05-12	Xencor, Inc.	HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
US20250179172A1 (en) *	2020-12-17	2025-06-05	Hainan Simcere Zaiming Pharmaceutical Co., Ltd.	Cd5 antibody and use thereof
EP4279515A4 (en) *	2021-01-12	2025-02-19	Nanjing Iaso Biotechnology Co., Ltd.	Fully human single-domain tandem chimeric antigen receptor (car) targeting cd5, and use thereof
KR20230152032A (ko)	2021-02-03	2023-11-02	모차르트 쎄라퓨틱스 인코포레이티드	결합제 및 이를 사용하는 방법
EP4305067A1 (en)	2021-03-09	2024-01-17	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and cldn6
JP2024509274A (ja)	2021-03-10	2024-02-29	ゼンコアインコーポレイテッド	Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
BR112023000666A2 (pt)	2021-04-12	2023-10-24	Academia Sinica	Imunógeno, composição imunogênica, método para induzir uma resposta imune contra um coronavírus 2 da síndrome respiratória aguda grave e uso da composição imunogênica
EP4332118A1 (en) *	2021-04-29	2024-03-06	Korea Research Institute of Bioscience and Biotechnology	Novel anti-cd5 chimeric antigen receptor and immune cell expressing same
JP2024518100A (ja)	2021-05-11	2024-04-24	マイエロイド・セラピューティクス，インコーポレーテッド	ゲノム組込みのための方法および組成物
CN113105547B (zh) *	2021-05-18	2022-04-08	福州迈新生物技术开发有限公司	抗cd5蛋白单克隆抗体及其细胞株、制备方法和应用
TW202334429A (zh)	2021-10-01	2023-09-01	中央研究院	Sars-cov-2棘蛋白特異性抗體及其用途
WO2023076876A1 (en)	2021-10-26	2023-05-04	Mozart Therapeutics, Inc.	Modulation of immune responses to viral vectors
US12077597B2 (en)	2021-11-24	2024-09-03	International-Drug-Development-Biotech	Anti-CD5 antibodies and methods of use thereof
US20230279080A1 (en) *	2021-12-27	2023-09-07	Academia Sinica	Antibody specific to spike protein of sars-cov-2 and uses thereof
WO2024039683A1 (en) *	2022-08-15	2024-02-22	Myeloid Therapeutics, Inc.	Compositions and methods for conditioning patients for cell therapy
EP4572772A1 (en)	2022-08-17	2025-06-25	Capstan Therapeutics, Inc.	Conditioning for in vivo immune cell engineering
AU2024255035A1 (en)	2023-04-08	2025-04-03	Rock Biomedical Inc.	Methods and compositions for targeted delivery by polymersomes
WO2024249954A1 (en)	2023-05-31	2024-12-05	Capstan Therapeutics, Inc.	Lipid nanoparticle formulations and compositions
WO2024258967A1 (en) *	2023-06-13	2024-12-19	Synthis Therapeutics, Inc.	Anti-cd5 antibodies and their uses
WO2025076113A1 (en)	2023-10-05	2025-04-10	Capstan Therapeutics, Inc.	Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en)	2023-10-05	2025-04-10	Capstan Therapeutics, Inc.	Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4312916C2 (de) *	1993-04-14	1995-03-23	Fresenius Ag	Arzneimittel zur Behandlung von Immunreaktionen

2009
- 2009-08-28 CN CN2009801336869A patent/CN102137873A/zh active Pending
- 2009-08-28 US US13/061,420 patent/US20110250203A1/en not_active Abandoned
- 2009-08-28 AU AU2009287164A patent/AU2009287164A1/en not_active Abandoned
- 2009-08-28 RU RU2011111640/10A patent/RU2011111640A/ru not_active Application Discontinuation
- 2009-08-28 WO PCT/DK2009/050218 patent/WO2010022737A1/en active Application Filing
- 2009-08-28 JP JP2011524187A patent/JP2012500815A/ja not_active Withdrawn
- 2009-08-28 KR KR1020117007230A patent/KR20110050541A/ko not_active Withdrawn
- 2009-08-28 EP EP09809275A patent/EP2328932A1/en not_active Withdrawn
- 2009-08-28 NZ NZ591153A patent/NZ591153A/xx not_active IP Right Cessation
- 2009-08-28 CA CA2735279A patent/CA2735279A1/en not_active Abandoned
- 2009-08-28 BR BRPI0917148A patent/BRPI0917148A2/pt not_active IP Right Cessation
- 2009-08-28 MX MX2011000970A patent/MX2011000970A/es not_active Application Discontinuation
- 2009-08-31 TW TW098129192A patent/TW201011045A/zh unknown
2010
- 2010-12-13 IL IL209975A patent/IL209975A0/en unknown
2011
- 2011-01-11 ZA ZA2011/00300A patent/ZA201100300B/en unknown

Also Published As

Publication number	Publication date
IL209975A0 (en)	2011-02-28
ZA201100300B (en)	2012-01-25
CN102137873A (zh)	2011-07-27
TW201011045A (en)	2010-03-16
KR20110050541A (ko)	2011-05-13
RU2011111640A (ru)	2012-10-10
MX2011000970A (es)	2011-03-15
CA2735279A1 (en)	2010-03-04
WO2010022737A1 (en)	2010-03-04
US20110250203A1 (en)	2011-10-13
NZ591153A (en)	2012-12-21
JP2012500815A (ja)	2012-01-12
EP2328932A1 (en)	2011-06-08
AU2009287164A1 (en)	2010-03-04

Publication	Publication Date	Title
BRPI0917148A2 (pt)	2015-12-01	anticorpos anti-cd5
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
PT2813570T (pt)	2018-02-12	Resumo
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
HRP20171011T1 (hr)	2017-09-22	ANTI-eMET ANTITIJELO
DK2370462T3 (da)	2014-09-08	Glucagon-analoger
DK2342317T3 (da)	2013-03-18	Hængende-dråbe-plade
DE602009000234D1 (de)	2010-11-11	msignals
BRPI0907376A2 (pt)	2015-07-14	Fotobiorretador
PT3045471T (pt)	2017-06-14	Resumo
DK3444343T3 (da)	2021-01-18	Polypeptider
BRPI0914649A2 (pt)	2015-07-07	Piprazolo-quinazolinas
DE602008003972D1 (de)	2011-01-27	Sitzrücklehnungsmechanismus
DE602008003521D1 (de)	2010-12-30	Sitzrücklehnungsmechanismus
EP2337798A4 (en)	2012-10-24	SPECIFIC ANTIBODIES OF THE ASB
FIC20240018I1 (fi)	2024-06-04	Vamoroloni
DK2342454T3 (da)	2013-10-28	Vindkraftanlæg
DK2335031T3 (da)	2019-08-26	In-line-måler
DK2336132T3 (da)	2014-04-07	Morpholinpurinderivat
DK2379557T3 (da)	2012-12-17	Aminopyrazol-forbindelse
BRPI0909633A2 (pt)	2015-09-22	anticorpos anti-tyrp1
DK2271613T3 (da)	2014-07-14	Hydroxymethylcyklohexylaminer
DE602008003970D1 (de)	2011-01-27	Strahlstromkalibriersystem
BRPI0907522A2 (pt)	2019-09-24	biarlamidas
DE112009000183A5 (de)	2011-02-03	Sicherheitsvorreiber

Legal Events

Date	Code	Title	Description
2016-09-06	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 6A E 7A ANUIDADES.
2016-12-20	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.